Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Zhong, Wen‐Zhao; Chen, Ke‐Neng; Chen, Chun; Gu, Chundong; Wang, Jun; Yang, Xue‐Ning; Mao, Weimin; Wang, Qun; Qiao, Guibin; Cheng, Ying; Xu, Lin; Wang, Changli; Chen, Mingwei; Kang, Xiaozheng; Yan, Wanpu; Yan, Hong‐Hong; Liao, Ri-Qiang; Yang, Jin‐Ji; Zhang, Xu‐Chao; Zhou, Qing; Wu, Yi‐Long

doi:10.1200/jco.19.00075

Public

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Published in Journal of Clinical Oncology • Jun 13, 2019

Authors:

Wen‐Zhao Zhong

Ke‐Neng Chen

Chun Chen

Abstract

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation-positive non–small-cell lung cancer. PATIENTS AND METHODS This was a multicenter (17 centers in China), open-label, phase II, rando...

Subject

Medicine

Erlotinib

Gemcitabine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!